Gopa Iyer
About
Gopa Iyer is a scholar working on Surgery, Oncology and Molecular Biology.
According to data from OpenAlex, Gopa Iyer has authored 52 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Surgery, 22 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Gopa Iyer's work include Bladder and Urothelial Cancer Treatments (33 papers), Urinary and Genital Oncology Studies (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Gopa Iyer is often cited by papers focused on Bladder and Urothelial Cancer Treatments (33 papers), Urinary and Genital Oncology Studies (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Gopa Iyer collaborates with scholars based in United States, United Kingdom and Japan. Gopa Iyer's co-authors include David B. Solit, Gil Redelman‐Sidi, Michael S. Glickman, Dean F. Bajorin, Jonathan E. Rosenberg, Samuel A. Funt, Hikmat Al‐Ahmadie, Ashley Marie Regazzi, Maria I. Carlo and Irina Ostrovnaya and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.
In The Last Decade
Gopa Iyer
42 papers receiving 295 citations
Peers
Gopa Iyer
Jordan Kardos United States
Chris J. de Witte Netherlands
Xi Ai China
Tanuj Banker United States
Ji Hyang Kim South Korea
Shuya Kaneko Japan
Corey Carter United States
Zhenjian Cai United States
Xiaoling Song China
Citations per year, relative to Gopa Iyer Gopa Iyer (= 1×)
peers
Jordan Kardos
Countries citing papers authored by Gopa Iyer
Since
Specialization
Citations
This map shows the geographic impact of Gopa Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gopa Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gopa Iyer more than expected).
Fields of papers citing papers by Gopa Iyer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gopa Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gopa Iyer. The network helps show where Gopa Iyer may publish in the future.
Co-authorship network of co-authors of Gopa Iyer
This figure shows the co-authorship network connecting the top 25 collaborators of Gopa Iyer. A scholar is included among the top collaborators of Gopa Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gopa Iyer. Gopa Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl).
2.
Guercio, Brendan J., Karissa Whiting, Ronak Shah, et al.. (2025). Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance). European Urology Open Science. 75. 80–88.
3.
Kotecha, Ritesh R., Andrea Knežević, Hyung Jun Woo, et al.. (2025). A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. European Urology Oncology. 8(4). 866–870.
4.
Iyer, Gopa, Hiromichi Ebi, Natalie Cook, et al.. (2025). A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.. Journal of Clinical Oncology. 43(5_suppl). 662–662.
5.
Das, Jeeban Paul, Ritesh R. Kotecha, Han Xiao, et al.. (2025). Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma. ESMO Open. 10(6). 105305–105305.
6.
Tallman, Jacob E., Florestan Koll, Sizhi Paul Gao, et al.. (2024). Abstract A029: Transcriptome analysis of variant histology bladder cancer reveals drug target heterogeneity. Clinical Cancer Research. 30(10_Supplement). A029–A029.
7.
Weir, Vanessa, et al.. (2024). Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma. JAAD Case Reports. 56. 40–44.
8.
Gupta, Aditi, Karissa Whiting, Niamh M. Keegan, et al.. (2024). Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).. Journal of Clinical Oncology. 42(16_suppl). 4569–4569.
9.
Chen, Ziyu, Karan Nagar, John R. Christin, et al.. (2024). Abstract 6006: Modeling antibody drug conjugate sensitivity using urothelial carcinoma patient-derived models. Cancer Research. 84(6_Supplement). 6006–6006.
10.
Lee, Elizabeth, Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300). Gynecologic Oncology. 176. S185–S185.
11.
Deming, Dustin A., Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).. Journal of Clinical Oncology. 41(4_suppl). TPS818–TPS818.
12.
Gordhandas, Sushmita, Beryl Manning‐Geist, Christina Henson, et al.. (2022). Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Scientific Reports. 12(1). 974–974.
13.
Sarfaty, Michal, Darren R. Feldman, Michael J. Morris, et al.. (2021). Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clinical Genitourinary Cancer. 19(3). e178–e183.
14.
Guercio, Brendan J., Gopa Iyer, Wajih Zaheer Kidwai, et al.. (2021). Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports in Oncology. 14(1). 430–438.
15.
Clinton, Timothy N., Nima Almassi, Nathan C. Wong, et al.. (2020). MP55-03 GENOMIC PREDICTORS OF PATHOLOGICAL UPSTAGING OF CLINICALLY LOCALIZED UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY. The Journal of Urology. 203. e838–e838.
16.
Pietzak, Eugene J., Hikmat Al‐Ahmadie, Dean F. Bajorin, et al.. (2019). “Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes. Translational Cancer Research. 8(Suppl 6). S642–S644.
17.
Fu, Xiaoling, Weixin Niu, Ji Li, et al.. (2017). Activating mutation ofPDGFRBgene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case report. Oncotarget. 8(46). 81709–81716.
18.
Redelman‐Sidi, Gil, Gopa Iyer, David B. Solit, & Michael S. Glickman. (2013). Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells. Cancer Research. 73(3). 1156–1167.
19.
Balar, Arjun Vasant, Gopa Iyer, Andrea B. Apolo, et al.. (2012). Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 30(15_suppl). 4581–4581.
20.
Iyer, Gopa, Michael J. Morris, Dana E. Rathkopf, et al.. (2011). A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology. 69(4). 1089–1097.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jordan Kardos Breakdown of academic impact, for papers by Chris J. de Witte Breakdown of academic impact, for papers by Xi Ai Breakdown of academic impact, for papers by Tanuj Banker Breakdown of academic impact, for papers by Ji Hyang Kim Breakdown of academic impact, for papers by Shuya Kaneko Breakdown of academic impact, for papers by Corey Carter Breakdown of academic impact, for papers by Zhenjian Cai Breakdown of academic impact, for papers by Xiaoling Song